Multidrug-resistant Mycobacterium tuberculosis: Molecular perspectives

Emerging Infectious Diseases

Volumn 4, Issue 2, 1998, Pages 195-209

  Rattan, Ashok ^a   Kalia, Awdhesh ^a   Ahmad, Nishat ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PEROXIDASE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE; STREPTOMYCIN;

AMINO ACID SUBSTITUTION; DRUG MECHANISM; INFECTION PREVENTION; INHIBITION KINETICS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031862229     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0402.980207     Document Type: Review

References (121)

1. Bloom BR, Murray CJL. Tuberculosis: Commentary on a reemergent killer. Science 1992;257:1055-64.
2. World Health Organization. Bridging the gaps: the world health report. Geneva: The Organization; 1995.
3. World Health Organization report on TB epidemic. Global TB programme. Geneva: The Organization; 1997.
4. Barnes P, Blotch AB, Davidson BT, Snyder Jr DE. Tuberculosis in patients with immuno-deficiency virus infection. N Engl J Med 1991;324:1644-50.
5. Kochi A, Vareldzis B, Styblo K Multi-Drug resistant tuberculosis and control. Res Microbiol 1993;144:104-10.
6. Bell RT. Tuberculosis of the 1990s: the quiet public health threat. Pa Med 1992;95:24-5.
7. Snyder DE Jr, Roper WL. The new tuberculosis. N Engl J Med 1992;326:703-5.
8. Freiden TE, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen JO, Dooley SW. The emergence of drug-resistant tuberculosis in New York city. N Engl J Med 1993;328:521-6.
9. Nosocomial transmission of multi-drug resistant tuberculosis among human immuno-deficiency virus infected patients - Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991;40:585-91.
10. Dooley SW, Jarvis WR, Martone WJ, Snyder DE Jr. Multi-Drug resistant tuberculosis [editorial]. Ann Intern Med 1992;117:257-8.
11. Edlin BR, Tokers JI, Greeko MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the Acquired Immuno-Deficiency syndrome. N Engl J Med 1992;326:1514-21.
12. Pearson ML, Jareb JA, Freiden TR, Crawford JT, Davis BJ, Dooley SN, et al. Nosocomial transmission of multi-drug resistant tuberculosis - a risk to patients and health care workers. Ann Intern Med 1992;117:191-6.
13. Iseman MD, Sbarbaro JA. The increasing prevalence of resistance to antituberculosis chemotherapeutic agents: implications for global tuberculosis control. Curr Clin Top Infect Dis 1992;12:188-204.
14. Cohn DL, Flavia B, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997;24:S121-30.
15. Initial therapy for tuberculosis in the era of multi-drug resistance: recommendations of the advisory council for the elimination of tuberculosis. MMWR Morb Mortal Wkly Rep 1993;42 (RR-7).
16. Mitchison DA. Mechanism of drug action in short-course chemotherapy. Bulletin International Union Against Tuberculosis 1985;65:30-7.
17. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med 1989;10:341-53.
18. Heifets LB, Lindohlm-Levy PJ. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis populations. American Review of Respiratory Diseases 1992;145:1223-5.
19. Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle and Lung Diseases 1994;75:1-7.
20. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994;264:388-93.
21. Davis J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-82.
22. Shimao T. Drug-resistance in tuberculosis control. Tubercle 1987;68(suppl):5-15.
23. Crofton J. The assessment and treatment of drug-resistance problems in tuberculosis. Journal of the Irish Medical Association 1970;63:75-8.
24. Grange JM. Drug-resistance and tuberculosis elimination. Bulletin International Union Against Tuberculosis and Lung Diseases 1990;65:57.
25. Youatt J. A review of the action of isoniazid. American Review of Respiratory Diseases 1969;99:729-49.
26. Shoeb HA, Bowman BU Jr, Ottolenghi AC, Merola AJ. Peroxidase-mediated oxidation of isoniazid. Antimicrob Agents Chemother 1985;27:399-403.
27. Maggliozzo RS, Marcinkeviciene JA. Evidence for isoniazid oxidation by oxypressors mycobaterial catalase-oxidase. Journal American Chemical Society 1996;118:11303-4.
28. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli. American Review of Tuberculosis 1954;69:471-2.
29. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
30. Zhang Y, Garbe T, Young D. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 1993;8:521-4.
31. Demple B, Halbrook J. Inducible repair of oxidative DNA damage in Escherichia coli. Nature 1983;304:466.
32. Sherman DR, Sabo PJ, Hickey MJ, Arain TM, Mahairas GG, Yuan Y, et al. Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci U S A 1995;92:6625-9.
33. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE III, Stover CK. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996;272:1641-3.
34. Chae HZ, Robinson K, Leslie B, Church GB, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain, alkyl hydroperoxide reductase and thiolspecific anti-oxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A 1994;91:7017-21.
35. Chae HZ, Chung SJ, Rhee SG. Thioredoxin-dependent-peroxide reductase from yeast. J Biol Chem 1994;269:276-0.
36. Sreevatsan S, Pan X, Zhang Y, Deretic V, Muser JM. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organims recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997;41:600-6.
37. Heym B, Stavropoulos E, Honore N, Domenech P, Saint-Joanis B, Wilson TM, et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997;65:1395-401.
38. Altamarino M, Marostenmaki J, Wong A, Fitzgerald M, Black WA, Smith JA. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994;160:1162-5.
39. Stoeckle MY, Guan L, Riegler N, Weitzman I, Kreiswirth B, Kornblum J, et al. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J Infect Dis 1993;168:1063-5.
40. Cockerill FR III, Uhi JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 1995;171:240-5.
41. Pretorius GS, Van Helden PD, Sergel F, Eisenach KD, Victor TC, et al. Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother 1995;39:2276-81.
42. Heym B, Alzavi PM, Honore N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995;15:235-45.
43. Rouse DA, Devito JA, Li Z, Byer M, Morris SL. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol 1996;22:583-92.
44. Jaber M, Rattan A, Kumar R. Presence of katG gene in isoniazid-resistant strains of Mycobacterium tuberculosis. J Clin Pathol 1996;49:945-6.
45. Kalia A, Ahmad N, Rattan A. Diagnosis of multi-drug resistant tuberculosis: comparison of traditional, radiometric and molecular methods [abstract]. In: Abstracts of the 20th International Congress of Chemotherapy; 29 Jun-3 Jul 1997; Sydney, Australia. Sydney: International Society of Chemotherapy; 1997. p. 211.
46. Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR Jr, et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994;344:293-8.
47. Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, et al. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
48. Morris SL, Bai Gh, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multidrug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995;171:954-60.
49. Johnsson K, Froland WA, Schultz PG. Overexpression, purification and characterization of the catalase-peroxidase, katG from Mycobacterium tuberculosis. J Biol Chem 1997;272:2834-40.
50. Rouse DA, Li Z, Baig M, Morris SL. Characterization of the katG and inhA. genes of isoniazid resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;30:2472-7.
51. Rosner JL. Susceptibility of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother 1993;37:2251-3.
52. Deretic V, Philipp W, Dhandyuthapani S, Mudd MH, Curcic R, Garbe T, et al. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol 1995;17:889-900.
53. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid resistance of Mycobacterium tuberculosis complex. Mol Microbiol 1996;19:1025-34.
54. Banerjee A, Dubnau E. Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
55. Bergler H, Wallner P, Ebeling A, Leitinger B, Fuchshlschler S, Aschauer H, et al. Protein EnvM is the NADH-dependent-enoyl-ACP-reductase (Fab1) of Escherichia coli. J Biol Chem 1994;269:5493-6.
56. Cole ST. Mycobacterium tuberculosis: drug-resistance mechanisms. Trends Microbiol 1994;2:411-5.
57. Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Sacchettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995;267:1638-41.
58. Quemard A, Sacchettini JC, Dessen A, Jacobs WR Jr, Blanchard JS, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995;34:8235-41.
59. Johnsson K, King DS, Schultz PG. Studies on the mechanism of action of isoniazid and ethionamide in chemotherapy of tuberculosis. Journal of American Chemical Society 1995;117:5009-10.
60. Takayama K, Schoenes HK, Armstrong EL, Boyle KW. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 1975;16:308-17.
61. Davidson LA, Takayma K. Isoniazid inhibition of the synthesis of mono-saturated long chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1979;16:104-5.
62. Mdluli K, Sherman DR, Hickey MJ, Kreiswirth BN, Morris S, Stover CK, Barry LE III, et al. Biochemical and genetic data suggest that inhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 1996;174:1085-90.
63. Woodley CL, Kilburn JO, David HL, Silcox VA. Susceptibility of mycobacteria to rifampin. Antimicrob Agents Chemother 1972;2:245-9.
64. Ovchinnikov YA, Monastyrskaya GS, Gubanov VV, Lipkin VM, Sverdlov ED, Kiver IF, et al. Primary structure of Escherichia coli RNA polymerase nucleotide substitution in the ß-subunit gene of rifampicin resistant rpoB255 mutant. Mol Gen Genet 1981;84:536-8.
65. Levin ME, Hatfull GF. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol Microbiol 1993;8:277-85.
66. Ovchinnikov YA, Monastryskaya, GS, Gubanov VV, Lipkin VM, Sverdlov ED, Kiver IF, et al. The primary structure of Escherichia coli RNA polymerase. Nucleotide sequence of rpoB gene and amino-acid sequence of the ß-subunit. Eur J Biochem 1981;116:621-9.
67. Jin D, Gross C. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that leads to rifampicin resistance. J Mol Biol 1988;202:45-58.
68. Telenti A, Imboden P, Marchesi F. Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
69. Telenti A, Imboden P, Marchesi F, Schidheini T, Bodmer T. Direct, automated detection of rifampicin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993;37:2054-8.
70. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels M, Salfinger M, et al. Characterization of rifampicin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994;38:2380-6.
71. Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreisworth RN, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase ß-subunit in rifampicin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994;32:1095-8.
72. Felmlee TA, Liu Q, Whelen AC, Williams D, Sommer SS, Persing DH. Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single strand conformation polymorphism and dideoxy fingerprinting. J Clin Microbiol 1995;33:1617-23.
73. Whelen AC, Felmlee TA, Hunt JM, Williams DL, Roberts GD, Stockman L, Persing DH. Direct genotype detection of Mycobacterium tuberculosis rifampicin resistance in clinical specimens by using single-tube heminested PCR. J Clin Microbiol 1995;33:556-61.
74. De Benhouwer, Lhiang HZ, Jannes G, Mijis W, Machtelinckx L, Rossau H, et al. Rapid detection of rifampin resistance in sputum and biopsy samples from tuberculosis patients by PCR and line probe assay. Tubercle and Lung Diseases 1995;76:425-30.
75. Cooksey RC, Morlock GP, Glickman S, Crawford JT. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol 1997;35:1281-3.
76. Telenti A, Persing DH. Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Res Microbiol 1996;147:73-9.
77. Kim BJ, Kim SY, Park B-H, Liu M-A, Park I-K, Bai GH, et al. Mutations in the rpoB gene in Mycobacterium tuberculosis that ineterfere with PCR-single strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol 1997;35:492-4.
78. Thomas JP, Baughan CO, Wilkinson RG, Shephard RG. A new synthetic compound with anti-tuberculous activity in mice: ethambutol (dextro-2,2'-[ethylenediimino]-di-1-butonol). American Review of Respiratory Diseases 1961;83:891-3.
79. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with HIV virus. N Engl J Med 1993;329:828-33.
80. Rastoggi N, Goh KS. Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-flurophenyl alanine. Antimicrob Agents Chemother 1990;34:2061-4.
81. Rastoggi N, Goh KS, Labrausse V. Activity of clathiromycin compared with those of other drugs against Mycobacteriumparatuberculosis andfurther enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother 1992;36:2843-6.
82. Takayama K, Armstrong EL, Kunugi KA, Kilburn JO. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. Antimicrob Agents Chemother 1979;16:240-2.
83. Kilburn JO, Takayama K. Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis. Antimicrob Agents Chemother 1981;20:401-4.
84. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989;33:1493-9.
85. Wolucka BA, McNeil MR, de Hoffman E, Chojnaki T, Brennan PJ. Recognition of the lipid intermediate for arabinogalactan/arabinomanan biosynthesis and its relation to the mode of action ethambutol on mycobacteria. J Biol Chem 1994;269:23328-35.
86. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, Inamine JM. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996;93:11919-24.
87. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Weites B, et al. The emb operon, a gene cluster of Mycobacetrium tuberculosis involved in resistance to ethambutol. Nat Med 1997;3:567-70.
88. Sreevatsan S, Stockbauer KE, Pan X, Kreisworth BM, Moghazeh SL, Jacobs WR Jr, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997;41:1677-81.
89. Konno K, Nagayama H, Oka S. Nicotinamidase in mycobacteria: a method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 1959;184:1743-4.
90. Konno K, Feldman FM, McDermot W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. American Review of Respiratory Diseases 1967;95:461-7.
91. Mackaness GB. The intracellular activation of pyrazinamide and nicotinamide. American Review of Tuberculosis 1953;74:718-28.
92. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-7.
93. Sreevatsan S, Pan X, Zhang Y, Kreisworth BN, Musser JM. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997;41:636-40.
94. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y, et al. Characterization of pncA. mutations in pyrazinamide resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41:540-2.
95. Hewlett D, Horn DL, Alfalfa C. Drug resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995;273:916-7.
96. Scorpio A, Collins D, Whipple D, Cave D, Bates J, Zhang Y. Rapid differentiation of bovine and human tubercule bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 1997;35:106-10.
97. Gay JD, de Young DR, Roberts GD. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M chelonei, M. forfuitre, and M. kansasii. Antimicrob Agents Chemother 1984;26:94-6.
98. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A 1976;73:3872-5.
99. Kirchausen T, Wang JC, Harrison SC. DNAgyrase and its complexes with DNA: direct observation by electron microscopy. Cell 1985;41:933-43.
100. Higgins NP, Peebles CL, Sugino A, Cozzarelli NR. Purification of the subunits of Escherichia coli DNA gyrase and reconstitution of enzyme activity. Proc Natl Acad Sci U S A 1978;75:1773-7.
101. Gellart M, O'Dea MH, Itoh T, Tomizava J. Novobiocin and coumeromycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A 1976;73:4474-8.
102. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of Nalidixic acid: purification of Escherichia coli nalA. gene product and its relationship to DNA gyrase and a novel nicking closing enzyme. Proc Natl Acad Sci U S A 1977;74:4667-71.
103. Kirkegaard K, Wand JC. Mapping the topography of DNA wrapped around gyrase by nucleolytic and chemical probing of complexes of unique DNA sequences. Cell 1981;23:721-9.
104. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is the DNA gyrase. Proc Natl Acad Sci U S A 1985;82:307-11.
105. Wilmont CJR, Critchlow SE, Eperon IC, Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 1994;242:351-63.
106. Lewis RJ, Tsai FTF, Wigley DB. Molecular mechanism of drug inhibition by DNA gyrase. Bioessays 1996;18:661-71.
107. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreisworth B, et al. Cloning and nucleotide sequencing of Mycobacterium tuberculosis gyrA. and gyrB genes and detection of quinolone resistant mutations. Antimicrob Agents Chemother 1994;38:773-80.
108. Rees RJ, Maxwell A. DNA gyrase. Structure and function. Crit Rev Biochem Mol Biol 1991;26:335-75.
109. Revel V, Cambau E, Jarlier E, Sougakoff W. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother 1994;38:1991-6.
110. Inderlied CB. Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance, and assays for activity in biological fluids. In: Lorain V, editor. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins, Baltimore; 1991. p. 134-197.
111. Benveinste R, Davies J. Mechanism of antibiotic resistance in bacteria. Annu Rev Biochem 1973;42:471-506.
112. Davies J, Wright JD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997;5:234-9.
113. Douglass J, Steyn LM. A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1993;167:1505-6.
114. Finken M, Kirschner P, Meier, A, Wrede A, Bottger EC. Molecular basis of streptomycin-resistance in Mycobacterium tuberculosis: alteration of the ribosomal protein S12 gene and point mutations within a functional 16S rRNA pseudoknot. Mol Microbiol 1993;9:1239-46.
115. Meier A, Kirschner P, Bange FC, Vogel U, Botger EC. Genetic alteration in streptomycin-resistance in Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994;38:228-33.
116. Nair J, Rouse DA, Bai GH, Morris SL. The rpsL gene and streptomycin resistance in single and multi-drug resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993;10:521-4.
117. Honore N, Cole ST. Streptomycin resistance in mycobacteria. Anitmicrob Agents Chemother 1994;38:238-42.
118. Woes CR, Gutell RR. Evidence for several higher order structural elements in ribosomal rRNA. Proc Natl Acad Sci U S A 1989;86:3119-22.
119. Shaila MS, Gopinathan RP, Ramakrishnan T. Protein synthesis Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin susceptible and resistant strains. Antimicrob Agents Chemother 1973;4:205-13.
120. Meier A, Sander P, Schaper KJ, Scholz M, Bottger EC. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2452-4.
121. Orita M, Suzuki Y, Sekiya T, Hayashi K Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:875-9.